TOP2A gene copy number change in breast cancer
Aims The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pathology 2014-05, Vol.67 (5), p.420-425 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 425 |
|---|---|
| container_issue | 5 |
| container_start_page | 420 |
| container_title | Journal of clinical pathology |
| container_volume | 67 |
| creator | Engstrøm, M J Ytterhus, B Vatten, L J Opdahl, S Bofin, A M |
| description | Aims The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in breast cancer-specific survival according to TOP2A and HER2. Methods In this study, TOP2A, HER2 and chromosome 17 copy number were assessed in 670 cases of breast cancer using in situ hybridisation techniques. Gene to chromosome ratios ≥2 were classified as amplification. TOP2A deletion (gene to chromosome ratio ≤0.8) or monosomy (only one signal for both gene and chromosome in more than 75% of nuclei) were classified as gene loss. Results A strong association between TOP2A change and HR and HER2 status was found. During the first 5 years after diagnosis, the risk of death from breast cancer was significantly higher for cases with HER2 amplification irrespective of TOP2A status. Conclusions TOP2A copy number change was strongly associated with HR and HER2 status and as a prognostic marker TOP2A is probably of limited value. |
| doi_str_mv | 10.1136/jclinpath-2013-202052 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3995265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4022623001</sourcerecordid><originalsourceid>FETCH-LOGICAL-b433t-61a38d6600374a8446d5dcbb2c58c4dd24caa5b14f9bafce08e0b9fb8ab95d23</originalsourceid><addsrcrecordid>eNqNkE1Lw0AQhhdRbK3-BCXgObqzX9lchFL8gkI99L7sbjZtQrOJm0TovzcltejNy8xhnnlneBC6BfwAQMVjaXeFb3S3jQkGOhSCOTlDU2AJiRkwcY6mGBOI04SJCbpq2xIPYAL0Ek0IY5iCFFP0sF59kHm0cd5Ftm72ke8r40Jkt9pvXFT4yASn2y6y2lsXrtFFrnetuzn2GVq_PK8Xb_Fy9fq-mC9jwyjtYgGaykwIjGnCtGRMZDyzxhDLpWVZRpjVmhtgeWp0bh2WDps0N1KblGeEztDTGNv0pnKZdb4LeqeaUFQ67FWtC_V34out2tRfiqYpJ4IPAffHgFB_9q7tVFn3wQ8vK0gkYJaATAeKj5QNddsGl58uAFYHy-pkWR0sq9HysHf3-73T1o_WAcAjYKryn5nfsbiKZQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781047189</pqid></control><display><type>article</type><title>TOP2A gene copy number change in breast cancer</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Engstrøm, M J ; Ytterhus, B ; Vatten, L J ; Opdahl, S ; Bofin, A M</creator><creatorcontrib>Engstrøm, M J ; Ytterhus, B ; Vatten, L J ; Opdahl, S ; Bofin, A M</creatorcontrib><description>Aims The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in breast cancer-specific survival according to TOP2A and HER2. Methods In this study, TOP2A, HER2 and chromosome 17 copy number were assessed in 670 cases of breast cancer using in situ hybridisation techniques. Gene to chromosome ratios ≥2 were classified as amplification. TOP2A deletion (gene to chromosome ratio ≤0.8) or monosomy (only one signal for both gene and chromosome in more than 75% of nuclei) were classified as gene loss. Results A strong association between TOP2A change and HR and HER2 status was found. During the first 5 years after diagnosis, the risk of death from breast cancer was significantly higher for cases with HER2 amplification irrespective of TOP2A status. Conclusions TOP2A copy number change was strongly associated with HR and HER2 status and as a prognostic marker TOP2A is probably of limited value.</description><identifier>ISSN: 0021-9746</identifier><identifier>EISSN: 1472-4146</identifier><identifier>DOI: 10.1136/jclinpath-2013-202052</identifier><identifier>PMID: 24403186</identifier><identifier>CODEN: JCPAAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm - genetics ; Biomarkers, Tumor - chemistry ; Biomarkers, Tumor - genetics ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Chromosomes ; Chromosomes, Human, Pair 17 ; DNA Copy Number Variations ; DNA Topoisomerases, Type II - genetics ; DNA-Binding Proteins - genetics ; Female ; Gene Amplification ; Gene Deletion ; Gene Dosage ; Gene expression ; Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Kaplan-Meier Estimate ; Medical prognosis ; Middle Aged ; Original ; Poly-ADP-Ribose Binding Proteins ; Predictive Value of Tests ; Prognosis ; Receptor, ErbB-2 - genetics ; Studies</subject><ispartof>Journal of clinical pathology, 2014-05, Vol.67 (5), p.420-425</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2014 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b433t-61a38d6600374a8446d5dcbb2c58c4dd24caa5b14f9bafce08e0b9fb8ab95d23</citedby><cites>FETCH-LOGICAL-b433t-61a38d6600374a8446d5dcbb2c58c4dd24caa5b14f9bafce08e0b9fb8ab95d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jcp.bmj.com/content/67/5/420.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://jcp.bmj.com/content/67/5/420.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>114,115,230,314,727,780,784,885,3196,23571,27924,27925,53791,53793,77600,77631</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24403186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Engstrøm, M J</creatorcontrib><creatorcontrib>Ytterhus, B</creatorcontrib><creatorcontrib>Vatten, L J</creatorcontrib><creatorcontrib>Opdahl, S</creatorcontrib><creatorcontrib>Bofin, A M</creatorcontrib><title>TOP2A gene copy number change in breast cancer</title><title>Journal of clinical pathology</title><addtitle>J Clin Pathol</addtitle><description>Aims The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in breast cancer-specific survival according to TOP2A and HER2. Methods In this study, TOP2A, HER2 and chromosome 17 copy number were assessed in 670 cases of breast cancer using in situ hybridisation techniques. Gene to chromosome ratios ≥2 were classified as amplification. TOP2A deletion (gene to chromosome ratio ≤0.8) or monosomy (only one signal for both gene and chromosome in more than 75% of nuclei) were classified as gene loss. Results A strong association between TOP2A change and HR and HER2 status was found. During the first 5 years after diagnosis, the risk of death from breast cancer was significantly higher for cases with HER2 amplification irrespective of TOP2A status. Conclusions TOP2A copy number change was strongly associated with HR and HER2 status and as a prognostic marker TOP2A is probably of limited value.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Neoplasm - genetics</subject><subject>Biomarkers, Tumor - chemistry</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Chromosomes</subject><subject>Chromosomes, Human, Pair 17</subject><subject>DNA Copy Number Variations</subject><subject>DNA Topoisomerases, Type II - genetics</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Female</subject><subject>Gene Amplification</subject><subject>Gene Deletion</subject><subject>Gene Dosage</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization</subject><subject>Kaplan-Meier Estimate</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Poly-ADP-Ribose Binding Proteins</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Studies</subject><issn>0021-9746</issn><issn>1472-4146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkE1Lw0AQhhdRbK3-BCXgObqzX9lchFL8gkI99L7sbjZtQrOJm0TovzcltejNy8xhnnlneBC6BfwAQMVjaXeFb3S3jQkGOhSCOTlDU2AJiRkwcY6mGBOI04SJCbpq2xIPYAL0Ek0IY5iCFFP0sF59kHm0cd5Ftm72ke8r40Jkt9pvXFT4yASn2y6y2lsXrtFFrnetuzn2GVq_PK8Xb_Fy9fq-mC9jwyjtYgGaykwIjGnCtGRMZDyzxhDLpWVZRpjVmhtgeWp0bh2WDps0N1KblGeEztDTGNv0pnKZdb4LeqeaUFQ67FWtC_V34out2tRfiqYpJ4IPAffHgFB_9q7tVFn3wQ8vK0gkYJaATAeKj5QNddsGl58uAFYHy-pkWR0sq9HysHf3-73T1o_WAcAjYKryn5nfsbiKZQ</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Engstrøm, M J</creator><creator>Ytterhus, B</creator><creator>Vatten, L J</creator><creator>Opdahl, S</creator><creator>Bofin, A M</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20140501</creationdate><title>TOP2A gene copy number change in breast cancer</title><author>Engstrøm, M J ; Ytterhus, B ; Vatten, L J ; Opdahl, S ; Bofin, A M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b433t-61a38d6600374a8446d5dcbb2c58c4dd24caa5b14f9bafce08e0b9fb8ab95d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Neoplasm - genetics</topic><topic>Biomarkers, Tumor - chemistry</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Chromosomes</topic><topic>Chromosomes, Human, Pair 17</topic><topic>DNA Copy Number Variations</topic><topic>DNA Topoisomerases, Type II - genetics</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Female</topic><topic>Gene Amplification</topic><topic>Gene Deletion</topic><topic>Gene Dosage</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization</topic><topic>Kaplan-Meier Estimate</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Poly-ADP-Ribose Binding Proteins</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Engstrøm, M J</creatorcontrib><creatorcontrib>Ytterhus, B</creatorcontrib><creatorcontrib>Vatten, L J</creatorcontrib><creatorcontrib>Opdahl, S</creatorcontrib><creatorcontrib>Bofin, A M</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Engstrøm, M J</au><au>Ytterhus, B</au><au>Vatten, L J</au><au>Opdahl, S</au><au>Bofin, A M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TOP2A gene copy number change in breast cancer</atitle><jtitle>Journal of clinical pathology</jtitle><addtitle>J Clin Pathol</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>67</volume><issue>5</issue><spage>420</spage><epage>425</epage><pages>420-425</pages><issn>0021-9746</issn><eissn>1472-4146</eissn><coden>JCPAAK</coden><abstract>Aims The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in breast cancer-specific survival according to TOP2A and HER2. Methods In this study, TOP2A, HER2 and chromosome 17 copy number were assessed in 670 cases of breast cancer using in situ hybridisation techniques. Gene to chromosome ratios ≥2 were classified as amplification. TOP2A deletion (gene to chromosome ratio ≤0.8) or monosomy (only one signal for both gene and chromosome in more than 75% of nuclei) were classified as gene loss. Results A strong association between TOP2A change and HR and HER2 status was found. During the first 5 years after diagnosis, the risk of death from breast cancer was significantly higher for cases with HER2 amplification irrespective of TOP2A status. Conclusions TOP2A copy number change was strongly associated with HR and HER2 status and as a prognostic marker TOP2A is probably of limited value.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>24403186</pmid><doi>10.1136/jclinpath-2013-202052</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9746 |
| ispartof | Journal of clinical pathology, 2014-05, Vol.67 (5), p.420-425 |
| issn | 0021-9746 1472-4146 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3995265 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Antigens, Neoplasm - genetics Biomarkers, Tumor - chemistry Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - pathology Chromosomes Chromosomes, Human, Pair 17 DNA Copy Number Variations DNA Topoisomerases, Type II - genetics DNA-Binding Proteins - genetics Female Gene Amplification Gene Deletion Gene Dosage Gene expression Gene Expression Regulation, Neoplastic Humans Immunohistochemistry In Situ Hybridization Kaplan-Meier Estimate Medical prognosis Middle Aged Original Poly-ADP-Ribose Binding Proteins Predictive Value of Tests Prognosis Receptor, ErbB-2 - genetics Studies |
| title | TOP2A gene copy number change in breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T18%3A30%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TOP2A%20gene%20copy%20number%20change%20in%20breast%20cancer&rft.jtitle=Journal%20of%20clinical%20pathology&rft.au=Engstr%C3%B8m,%20M%20J&rft.date=2014-05-01&rft.volume=67&rft.issue=5&rft.spage=420&rft.epage=425&rft.pages=420-425&rft.issn=0021-9746&rft.eissn=1472-4146&rft.coden=JCPAAK&rft_id=info:doi/10.1136/jclinpath-2013-202052&rft_dat=%3Cproquest_pubme%3E4022623001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781047189&rft_id=info:pmid/24403186&rfr_iscdi=true |